KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.98
+1.42%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 122.45x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.83x
- Price / sales
- 14.51x
- Price / cash flow
- -4.54x
Enterprise value
- Enterprise value
- -$24.1M
- EV / sales
- -1.60x
- EV / EBITDA
- 0.29x
- EV / EBIT
- 0.24x
- Market cap
- $217.8M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026